economist semaglutide Competition will make weight-loss drugs better, cheaper and bigger Drugmaker Novo Nordisk slashes Wegovy

Patients who attempt to rush their dose escalation or inject multiple times per week report higher rates of discontinuation due to intolerable nausea, making them less likely to achieve long-term weight loss goals

In the main data collection phase across 15 countries (n=68,411), response rates ranged from 80.1% to 100%, with most countries achieving rates above 90%

Additionally, if patients are restricting their diet too severely alongside Wegovy, this might contribute to cravings for high-energy foods

: , , ,

Effect of CIN-109, a novel GDF-15 analog, on body weight and composition in subjects with obesity